tion) [1] but has not yet proven superior compared with conservative treatment in randomized controlled trials.
The MitraClip device may be a game-changer in this specific patient population. After approximately 10 years of use and more than 60,000 implantations worldwide, the COAPT trial for the first time showed a huge survival benefit after 2 years in heart failure patients with significant functional MR who were treated with the MitraClip [2] . In the COAPT trial 614 heart failure patients with significant MR from 78 American and Canadian centers were randomly assigned to MitraClip in addition to optimal medical treatment (device group) or optimal medical treatment alone (control group). An independent echocardiographic core laboratory had to confirm MR severity, left ventricular systolic function (required to range from 20% to 50% ejection fraction), left ventricular dimensions, and a high probability that the mitral valve could be repaired with the MitraClip system. Patients were only eligible if they were symptomatic despite optimal medical treatment with a New York Health Association (NYHA) score ≥2. The local heart team had to deem surgery inappropriate. The primary end-point in terms of effectiveness was all-cause hospitalization for heart failure at 2 years. 302 patients were assigned to the device group, and 312 to the control group. At 2 years, the primary endpoint was significantly more often met in the control group (hazard ratio, 0.53; 95% confidence interval, 0.4-0.7; p < 0.0001). Furthermore, all-cause mortality was reduced by 17% in the device-group (hazard ratio 0.62, number needed to treat at 24 months 5.9). These results indicate a major advancement in the treatment of heart failure. A recent meta-analysis including 2121 heart failure patients confirmed the findings of COAPT by demonstrating a significant survival benefit in those treated with the MitraClip device [4] . 692 Transcatheter mitral valve repair using the MitraClip: which patients benefit most?
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Apart from the benefits with respect to heart failure hospitalization and death, small series have shown that a decrease of pulmonary pressures after reducing MR severity with the MitraClip device rendered endstage heart failure patients eligible for heart transplantation who previously had been rejected due to inappropriate hemodynamics [5] .
Why, however, were the fabulous results of COAPT not seen at all in the Mitra-FR trial? This is one of the main controversies among heart failure specialists right now. The Mitra-FR trial randomized 304 heart failure patients with significant MR at 37 centers in France to either MitraClip implantation in addition to optimal medical therapy (device group) or optimal medical treatment alone (control group). All echocardiograms were evaluated in a core laboratory that had to confirm MR severity and that left ventricular ejection fractions ranged from 15% to 40%. Similarly to COAPT, surgery had to be deemed inappropriate by the local heart team. Follow-up was shorter than in COAPT-12 months in comparison to 24 months-and the primary endpoint was a composite of unplanned hospitalization for heart failure and all-cause death. In the study 152 patients were randomly assigned to each group. After 1 year, no difference in the primary endpoint was observed between the device and control groups (p = 0.53).
Since presentation of both trials, numerous potential explanations for the differences in findings in COAPT and Mitra-FR have been put forward. Among them are considerations concerning inclusion criteria and background medical therapy. The COAPT trial enrolled patients between 2012 and 2017, Mitra-FR between 2013 and 2017 but only with half as many patients. Patients on medical treatment improved in Mitra-FR during the study period (patient-study benefit?) while they did not in COAPT.
Certainly, further (sub)analyses of both trials and future upcoming studies will shed more light on the most important remaining question: which are the patients who will benefit most from MitraClip implantation?-Those with primary MR deemed inoperable?-End-stage heart failure patients not eligible for heart transplantation due to high pulmonary pressures?-Among heart failure patients with secondary MR those who have a more advanced disease or a less advanced disease? Exciting times are ahead for the MitraClip community.
